BRAIST: The Brace Trial That Changed Scoliosis Care

Ava

Welcome to the show everyone! I'm Ava, here with David. I want to jump straight into 2013, when the New England Journal of Medicine published the BRAIST trial. For decades, the scoliosis community was locked in this unresolved debate: does putting a teenager in a rigid spinal brace actually stop their curve from progressing to the point of surgery, or are we just treating these kids for no clinical benefit?

David (2)

It was a proper clinical battleground, wasn't it? Before 2013, we had mostly observational studies, but the results were equivocal. You had some papers claiming spinal braces cut surgery rates to zero, and others showing absolutely no difference compared to just watching and waiting. So, Stuart Weinstein and his team set out to do what many thought was impossible: a rigorous, multi centre randomised controlled trial.

Ava

Exactly. They set up the Bracing in Adolescent Idiopathic Scoliosis Trial across twenty five institutions in the US and Canada, aiming for three hundred and eighty4 patients. But they ran into a roadblock right away. Families did not want to be randomised. Recruitment was incredibly slow because parents and kids either firmly wanted the orthosis or absolutely refused to wear one.

David (2)

Right, so they did something quite clever. To save the trial from collapsing, they added a preference cohort alongside the randomised one. So if a family agreed to let a computer flip a coin, they went into the randomised group. If they had a strong treatment preference, they went into the preference group but followed the exact same clinical protocol. That gave them two hundred and forty two patients for the final analysis.

Ava

And that hybrid design saved the study. But then, in January 2013, during a routine interim review, the data and safety monitoring board looked at the early results and stopped the trial completely. They cut it short because the efficacy of the orthosis was so overwhelmingly positive that it was deemed unethical to keep the control group under observation only.

David (2)

Unethical to continue! That is the ultimate mic drop in clinical research. When you look at the primary analysis, seventy two percent of the braced patients achieved treatment success, meaning they reached skeletal maturity without their curve progressing to fifty degrees or more. Compare that to only forty eight percent in the observation group.

Ava

And in the randomised only cohort, the difference was even wider. The success rate was seventy five percent for those assigned to bracing versus just forty two percent for observation. That is a significant difference, but as an engineer, David, I know you want to look at how they actually measured who was wearing what.

David (2)

That's right, Ava. Because historically, clinical studies on orthoses relied on patient diaries. And let's be honest, asking a thirteen year old to write down exactly how many hours they wore a restrictive plastic brace every day is a recipe for fiction. So the BRAIST researchers did something brilliant: they embedded tiny, objective temperature loggers, either a StowAway or a TidbiT sensor, directly into the plastic.

Ava

Those little StowAway sensors are fascinating. They programmed them to log the temperature every fifteen minutes. If the sensor registered twenty eight degrees Celsius or higher, it meant the orthosis was actively being worn against the body. If it was lower, the brace was sitting on the floor or in a locker.

David (2)

Twenty eight degrees Celsius! That is the perfect threshold because it completely eliminates guesswork. And when they downloaded that temperature data every six months, the true story emerged. The prescribed wear time was eighteen hours a day, but the actual average wear time across the cohort was only twelve point one hours.

Ava

Twelve point one hours, so they were falling quite short of the prescription. But this is where the dose response curve comes in. When the researchers plotted the objective wear hours against treatment success, duration of brace wear was positively associated with the rate of success.

David (2)

It is a textbook dose response curve. For the patients in the lowest quartile, who wore the orthosis for fewer than six hours a day, the success rate was only forty one percent. That is actually worse than the forty eight percent success rate of the group that wore no brace at all. Essentially, wearing it less than six hours is completely useless.

Ava

But then look at the other end of the curve. For the patients who actually wore the brace for twelve point nine hours or more per day, their success rate skyrocketed to between ninety and ninety three percent.

David (2)

Ninety three percent success. That is a staggering number for a non surgical intervention. It completely changes the conversation we have with families. We don't have to guilt trip a teenager into hitting an unattainable eighteen hours; we can show them the data. If they can average just thirteen hours a day, they have a nine in ten chance of avoiding major spinal surgery.

Ava

And that is why this paper is so vital for practitioners. It transforms the orthosis from a passive device we hope they wear into a dose dependent treatment. It gives us the empirical backing to say to a patient, "Look, every hour you put into this brace directly protects your spine." It shifts the whole dynamic from parental policing to collaborative, evidence based shared decision making.

David (2)

It really does. It shows that in paediatric orthotics, the engineering of the device is only half the battle; the other half is understanding the human engineering of concordance. We highly recommend everyone read the full landmark paper. It is titled, Effects of Bracing in Adolescents with Idiopathic Scoliosis, published in the New England Journal of Medicine.

Ava

That is a perfect place to leave it. Thank you for listening to the Prosthetic and Orthotic Research Brief.

David (2)

Bye for now, and thanks for listening.